NCT01179412已完成4 期
Treatment of Epidemic Keratoconjunctivitis With 2% Povidone-iodine
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 172
- 试验地点
- 1
- 主要终点
- the recovery rate within one week of treatment
研究概览
简要总结
The purpose of this study is to determine the outcomes of treating epidemic keratoconjunctivitis with 2% povidone-iodine.
详细描述
The study design was a prospective interventional case series. Our institutional ethical committee approved the study protocol in April 2004. We performed this study between July 2004 and December 2009. During this period, there were 2 episodes of EKC epidemic. The first episode was in 2006 and the second in 2009.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients who were diagnosed with EKC at the outpatient ophthalmic unit
排除标准
- •children younger than six years
- •women being pregnant or during lactation
- •history of allergy to povidone-iodine
- •prior ocular surgery
- •contact lens usage and chronic eye diseases with current eye medications.
研究组 & 干预措施
2% povidone-iodine
Experimental
干预措施: 2% povidone-iodine (Drug)
结局指标
主要结局
the recovery rate within one week of treatment
时间窗: 1 week
次要结局
- drug tolerability(1 week)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseDry Eye SyndromesKeratoconjunctivitis SiccaNCT02188160Kala Pharmaceuticals, Inc.150
Unknown
2 期
Safety and Efficacy Study of an Ophthalmic Solution in Patients With Age-Related CataractCataractNCT00793091Chakshu Research, Inc.80
已完成
3 期
Safety and Efficacy of KPI-121 in Subjects With DEDKerato Conjunctivitis SiccaNCT03616899Kala Pharmaceuticals, Inc.901
已完成
3 期
Safety and Efficacy of KPI-121 in Subjects With Dry Eye DiseaseDry Eye SyndromesKeratoconjunctivitis SiccaNCT02813265Kala Pharmaceuticals, Inc.918
已完成
3 期
Safety and Efficacy of KPI-121 Compared to Placebo in Subjects With Dry Eye DiseaseDry Eye SyndromesKeratoconjunctivitis SiccaNCT02819284Kala Pharmaceuticals, Inc.909